Knights of Columbus Asset Advisors LLC Acquires Shares of 12,652 Blueprint Medicines Co. (NASDAQ:BPMC)

Knights of Columbus Asset Advisors LLC acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,652 shares of the biotechnology company’s stock, valued at approximately $1,104,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BPMC. Swiss National Bank lifted its stake in shares of Blueprint Medicines by 1.6% in the third quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock worth $10,748,000 after buying an additional 1,800 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Blueprint Medicines in the third quarter worth about $475,000. Advisors Asset Management Inc. lifted its stake in shares of Blueprint Medicines by 17.6% in the third quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company’s stock worth $467,000 after buying an additional 756 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Blueprint Medicines in the third quarter worth about $6,465,000. Finally, Intech Investment Management LLC purchased a new position in shares of Blueprint Medicines in the third quarter worth about $1,712,000.

Insider Activity at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the transaction, the director now owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,334 shares of company stock worth $3,103,512. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Price Performance

Shares of BPMC opened at $88.72 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock has a market cap of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58. The firm has a 50-day simple moving average of $99.47 and a two-hundred day simple moving average of $93.88. Blueprint Medicines Co. has a 1-year low of $80.68 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.